Neuronostics raises £300k in seed funding from QantX Ventures to advance clinical support systems.
The seed round was backed by private investors establishing QantX Ventures to fund clinical development.
Neuronostics is a medical technology start-up that develops mathematical and computational tools to improve the diagnosis and treatment of neurological conditions. Based in the UK, the company creates digital biomarkers like BioEP to enhance standard clinical recordings.
Neuronostics has secured £300k in seed funding from a group of private investors establishing QantX Ventures. The capital will support the ongoing development of the company's clinical decision support systems and smartphone applications.
The firm has created patented technology designed to deliver faster and more accurate epilepsy diagnoses. By employing mathematical modelling and advanced analytics on routine clinical data, the software assesses the risk of future seizures.
The injection of funds arrives as Neuronostics prepares to secure CE marking for its BioEP product later in the year. The company has previously collected several accolades, including recognition from MediLink UK and TechSW.
Investor perspective
"We are excited to become part of the Neuronostics journey, they have pioneered innovative technology that will make a significant positive difference to the lives of many people around the world."
Richard Haycock
Co-Founder, QantX Ventures
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
Categories
About the company
Neuronostics
Neuronostics develops digital biomarkers and software to improve the diagnosis of neurological conditions.